Configuration: CDOA-9165EFTK : AMP, BAR, BUP, BZO, COC, mAMP, MDMA, MTD, OPI-300, OXY, PCP, THC + ETG, FEN, K2, TRA
For a comprehensive discussion on drug of abuse testing including typical detection time periods see the DRUG TESTING FAQ
An all inclusive sixteen (16) panel immunoassay* for the simultaneous, specimen collection and screening for multiple drugs of abuse and their metabolites in human urine using one self-contained testing and sample collection device. This safe, accurate and economical testing system is used to obtain a rapid, visual, qualitative result indicating drug usage or abuse within a few minutes. This product will not test for quantitative measurements of drug concentrations in the body but will indicate their presence at or above minimum concentrations established by the NIDA and the World Health Organization.
The SAFElife Cup 16 in 1 incorporates a built-in lateral flow, multi-panel, chromo-graphic immunoassay for the detection and identification of AMP, BAR, BUP, BZO, COC, mAMP, MDMA, MTD, OPI-300, OXY, PCP, THC + ETG, FEN, K2, TRA in human urine at the standard minimum cut-off concentration levels based on the following federal (NIDA) and world (WHO) guidelines:
*While Methamphetamine tests will generally detect MDMA (Ecstasy), an MDMA specific test is recommended when screening specifically for MDMA or Ecstasy use.
The SAFElife 16 in 1 Cup combination specimen cup and multi-panel drug screen maximizes the simplicity and economics of drug testing programs. Testing is accomplished by simply obtaining a sample specimen. Thereafter the process is completely automatic. Results are read directly from the specimen container. The test container also provides an affixed identification label for recording test documentation of date, time, test subject ID etc. Additionally, the screw top container can be sealed for refrigerated storage or transport. Exposure to biological hazards is eliminated as there is no sample handling or device transfer required in the the testing process. This convenient, portable one-step sixteen panel testing device can be administered any time, at any place, and provide a 98+% accurate and definitive "yes or no" result in about five minutes without the costly and time consuming process of clinical analysis.
Automatically upon specimen collection, the SAFElife container begins to develop test results. Lateral flow of the sample across the test panels will begin and depending on the specific target drug panel, control lines and negative test lines may be observed developing in the test panels within thirty to sixty seconds. However, test results should not be read until the "result ready" indicator turns red. Any line, no matter how faint, appearing under the control line in the target drug test panel is a negative test for that target drug or drug metabolite. Drugs and drug metabolites remain at detectable levels in the human body for various periods of time after use depending on a number of different factors. For a brief discussion and chart regarding the half-life and detectable periods for drugs of abuse see the Drug FAQ.
The SAFElife Compact Cup 16 in 1 is available in packs of 25, 50, 100 or 250 test packs. For wholesale drug test quantities exceeding 250 units please contact us for special volume pricing. Complete use and background information including laboratory testing results, cross reaction charts, drug characteristics and other useful information is included with each test kit. The SAFElife Cup 16 in 1 is 98+% accurate when used in strict accordance to procedural instructions and is approved by the FDA, method and claims.
For bulk quantity pricing of five hundred (500) units or more please contact us at Customer Service.
*This immunoassay provides a preliminary, first-line analytical test result. A more specific alternative chemical method can be used in order to obtain a confirmed laboratory analytical result. Gas chromatography/mass spectrometry (GCIMS) has been established as the preferred confirmatory method by the National Institute on Drug Abuse (NIDA). Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.